Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)

  • End date
    Apr 29, 2025
  • participants needed
  • sponsor
Updated on 13 June 2022
body mass index
primary lateral sclerosis


This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an openlabel, longterm extension period.

Study ACT16970 consists of 2 parts (A and B) as follows:

Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 weeks before Day 1.

On Day 1 of Part A, participants will be randomized in a 2:1 ratio to the SAR443820 treatment arm or matching placebo arm as listed below:

Treatment arm: SAR443820, BID

Placebo arm: Placebo, BID

Randomization will be stratified by the geographic region of the study site, region of ALS onset (bulbar vs other areas), use of riluzole (yes vs no), and use of edaravone (yes vs no). Participants will attend inclinic study assessments at baseline (Day 1), Week 2, Week 4, Week 8, Week 16, and Week 24, and will receive a phone call at Week 12 and Week 20. After successful completion of Part A, all participants will rollover to Part B. The Week 24 Visit is the end of Part A and the beginning of Part B.

Part B is an open label, longterm extension period that starts from the end of Part A (Week 24) and continues up to Week 106. The objectives of Part B are to further determine the safety and efficacy of longterm SAR443820 treatment. The treatment assignment of participants in Part A will remain blinded to Investigators, participants, and site personnel until the end of Part B. Every participant will receive BID oral tablets of SAR443820 in Part B.


Part A of the study will last for 24 weeks, and participants will receive BID oral SAR443820 or placebo in a doubleblind fashion for 24 weeks. Participants who successfully complete double blind Part A will rollover to open label Part B.

Part B begins at the end of Week 24 and continues up to Week 106. All participants will receive BID oral tablets of SAR443820 in Part B.

The study duration includes an up to 4-week screening period, 24-week double blind treatment period in Part A, 80-week open label treatment period in Part B, and 2-week post treatment follow up period, with a maximum total study duration of 110 weeks.

Condition Amyotrophic Lateral Sclerosis
Treatment Placebo, SAR443820
Clinical Study IdentifierNCT05237284
Last Modified on13 June 2022


Yes No Not Sure

Inclusion Criteria

Type of participant and disease characteristics
Male or female, 18-80 years of age (inclusive)
Diagnosis of possible, clinically probable ALS, clinically probable laboratorysupported ALS, or clinically definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria
Time since onset of first symptom of ALS ≤2 years
Slow Vital Capacity (SVC) ≥60% of the predicted value
Be able to swallow the study tablets at the screening visit
Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study
Either not currently receiving edaravone or on the approved standard schedule of edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue edaravone treatment throughout the duration of the study
Weight : Participants with a body weight no less than 45 kg and body mass index no less
than 18 kg/m2
Female participants with childbearing potential are eligible to participate if they are not
pregnant or breastfeeding and agree to use adequate contraceptive method during study
intervention period and for at least 32 days after the last dose of study drug
Male participants must agree to use highly effective contraceptive method during the study
period and for at least 92 days following their last dose of the study drug. Male
participants must not donate sperms for the duration of study and 92 days after last dose
of study drug

Exclusion Criteria

A history of seizure (History of febrile seizure during childhood is allowed)
Having central IV lines, such as a peripherally inserted central catheter (PICC) or midline
or port a cath lines
With significant cognitive impairment, psychiatric disease, other neurodegenerative
disorder (eg, Parkinson disease or AD), substance abuse, or any other condition that would
make the participants unsuitable for participating in the study or could interfere with
assessment or completing the study in the opinion of the Investigator
History of recent serious infection (eg, pneumonia, septicemia) within 4 weeks of the
screening visit; infection requiring hospitalization or treatment with IV antibiotics
antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection
(such as tuberculosis) deemed unacceptable as per the Investigator's judgment
With active herpes zoster infection within 2 months prior to the screening visit
A documented history of attempted suicide within 6 months prior to the screening visit
present with suicidal ideation of category 4 or 5 on the Columbia Suicide Severity Rating
Scale (C-SSRS ), or in the Investigator's judgment are at risk for a suicide attempt
History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or
another medically significant illness other than ALS precluding their safe participation in
this study
Participants who are pregnant or are currently breastfeeding
A known history of allergy to any ingredients of SAR443820
Prior/concomitant therapy
Currently or previously treated with any strong or moderate CYP3A4 inhibitors or
strong CYP3A4 inducers listed in Appendix 10 of the protocol within the specified
washout period before the screening visit
Received a live vaccine within 14 days before the screening visit
Participants with concurrent participation in any other interventional clinical study or
who have received treatment with another investigational drug within 4 weeks or 5 halflives
of the investigational agent before the screening visit, whichever is longer
Participants who have received stem cell or gene therapy for ALS at any time in the past
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST ) >3.0 × upper limit of
normal (ULN )
Bilirubin >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated
bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is
Serum albumin <3.5 g/dL
Estimated glomerular filtration rate <60 mL/min/1.73 m2 (Modification of Diet in Renal
Disease [MDRD])
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note